Pfizer Partner Looking to Mix mRNA Vaccine with Chinese Products
China’s state-run
Global Times on Thursday reported that BioNTech, the German company that partnered with American company Pfizer to produce its coronavirus vaccine, is “considering to evaluate” mixing its mRNA product with the vaccine manufactured by China’s Fosun Pharma.
This consideration and evaluation is part of the Chinese government’s approval process for the Pfizer vaccine. BioNTech CEO Ugur Sahin said his company’s talks with Chinese officials have been “encouraging.”
According to the
Global Times, the BioNTech vaccine will probably be “landing” soon in Shanghai, where Fosun Pharma is based, and also hosts a sizable population of foreigners who “want a BioNTech’s shot for vaccine recognition when returning to their homeland.” Delivery drills for vaccine supply chains in China are reportedly underway. Chinese state media outlets make a point of not referring to the vaccine by the
China to Hollywood: Stop ‘Randomly Mixing Chinese Elements’ into Movies
China’s state-run
Global Times on Thursday told Hollywood it needs to do more than just throw a few “Chinese elements” into big-budget films if it wants to succeed at the Chinese box office, which surpassed the American box office during the Wuhan coronavirus pandemic.
The
Global Times editorial offered few concrete suggestions for how American films could compete more effectively in China, whose film industry has begun producing “homegrown” big-budget features that frequently outperform even recent Hollywood successes like
Godzilla vs. Kong.
“The top ten most anticipated films during China’s May Labor Day holiday are all domestic films, including Zhang Yimou’s first spy thriller